Agios Pharmaceuticals, Inc. reports developments as a commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its recurring updates center on mitapivat, an oral pyruvate kinase activator marketed as PYRUKYND® and AQVESME™, including product revenue, U.S. and ex-U.S. commercialization, thalassemia approvals, and activity in pyruvate kinase deficiency, sickle cell disease, and other hemolytic anemias.
Company news also covers FDA interactions, supplemental application activity, conference presentations, and pipeline progress for tebapivat, a next-generation PK activator, and other rare disease programs. International commercialization themes include regulatory approvals and distribution activity in Gulf Cooperation Council markets through NewBridge Pharmaceuticals.
Agios Pharmaceuticals (Nasdaq: AGIO) announced a $905 million purchase agreement with Royalty Pharma for the acquisition of its 15% royalty on potential U.S. net sales of vorasidenib, an oral dual inhibitor for IDH-mutant diffuse glioma. Upon FDA approval of vorasidenib, Agios will receive an upfront payment of $905 million and retain rights to a $200 million milestone payment from Servier, totaling $1.1 billion. The PDUFA action date is set for August 20, 2024. Agios will maintain a 3% royalty on annual U.S. net sales over $1 billion. This transaction is expected to boost Agios' financial flexibility and support future product launches and pipeline expansion.
Agios Pharmaceuticals announced it will present key clinical and translational data on rare blood disorders at the European Hematology Association 2024 Hybrid Congress in Madrid from June 13-16, 2024.
The presentations will include data from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia, highlighting efficacy and safety results.
Additional sessions will cover quality of life data from ENERGIZE and the design of the Phase 3 RISE UP study for sickle cell disease.
Agios will also share real-world data on pyruvate kinase deficiency and explore mitapivat's potential in other rare hemolytic anemias.
The company will host a virtual investor event on June 16, 2024, to discuss these findings.
Agios Pharmaceuticals, a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, will present at the BofA Securities 2024 Health Care Conference on May 16, 2024. The presentation will be live-streamed on the company's website, with a replay available for at least two weeks.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 14, 2024. The presentation is scheduled for 8:00 a.m. ET and will focus on the company's innovative therapies for rare diseases. Investors can access the live webcast on the company's website and a replay will be available for two weeks after the event.
Agios Pharmaceuticals, Inc. reported positive results from the Phase 3 ENERGIZE study of mitapivat in thalassemia. Mitapivat has potential as the first approved therapy for all thalassemia subtypes. The company posted $8.2 million in net revenue for PYRUKYND® in Q1 2024. Agios also disclosed upcoming milestones in sickle cell disease, pediatric PK deficiency, and lower-risk Myelodysplastic Syndromes. Financially, the company had $714.3 million in cash, cash equivalents, and marketable securities as of March 31, 2024. Agios aims to fund operations until at least 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.